ASO/siRNA
Biosol is expanding its biologics portfolio to include future capabilities in antisense oligonucleotide and siRNA technologies.
Designed to support emerging therapeutic modalities, the platform will focus on enabling development, characterization and manufacturing readiness for nucleic acid-based therapies.
Capabilities Include:
- Development Capabilities
- Manufacturing Readiness